|
|
|
|
29
|
Sun, 8/8/2021,
1:30 PM -
3:20 PM
|
Virtual
|
|
Statistical Issues Specific to Therapeutic Areas, Power and Sample Size Calculations, and Trial Monitoring — Contributed Speed
|
|
Biopharmaceutical Section
|
|
Chair(s): Jonathan Moscovici, QuintilesIMS
|
|
|
|
1:35 PM
|
A Bayesian Network Meta-Analysis on Treatments of Brain Metastases in Patients with Non-Small Cell Lung Cancer
Uma Siangphoe, Johnson and Johnson
|
|
1:40 PM
|
On Characterizing Survival Curve of CAR-T Cell Therapy
xiaoling wu, Legend Biotech
|
|
1:45 PM
|
On Treatment Effect in Sequential Parallel Comparison Design
Xiaoyan Liu, Boston University; Zifei Han, University of International Business and Economics; Chanmin Kim, Sungkyunkwan University; Gheorghe Doros, Boston University
|
|
1:50 PM
|
WITHDRAWN: Comparison of Methods for Adjusting for Crossover in Oncology Trials
Jin Zhang, Merck
|
|
1:55 PM
|
Handling Multiple Imputation in Wilcoxon Signed-Rank Test: A Case Study Applied to a Hemophilia Clinical Trial
Eunhee Hwang, Pfizer Inc; Joseph Cappelleri, Pfizer Inc; Satrajit Roychoudhury, Pfizer Inc.; Dan Meyer, Pfizer
|
|
2:00 PM
|
An Alternate Method to Find the Confidence Interval for the Difference Between Two Proportions of Rare Event
Ruji Yao, Merck & Co., Inc.; Amarjot Kaur, Merck & Co., Inc.; qing li, Merck & co., Inc.
|
|
2:05 PM
|
A Flexible Ensemble Learning Method for Survival Extrapolation
Meijing Wu, Abbvie Inc.; Ran Dai, University of Nebraska Medical Center ; Yabing Mai, Boehringer Ingelheim; Weili He, AbbVie
|
|
2:10 PM
|
Methods for Vaccine Efficacy in a Fixed Duration Design with Censoring
Ying Zhang, Merck & Co., Inc.; G. Frank Liu, Merck Sharp & Dohme Corp.; Radha A Railkar, Biostatistics and Research Decision Sciences, Merck & Co., Inc.
|
|
2:15 PM
|
Novel Measures of Treatment Efficacy Under Delayed Treatment Effects
Kijoeng Nam, Merck & Co., inc. ; Nicholas Henderson, University of Michigan; Dai Feng, AbbVie Inc.
|
|
2:20 PM
|
Sample Size Reestimation for the Finkelstein and Schoenfeld Test Statistic for a Composite Endpoint with Two Components
Thomas Zhou, Boston University; Joseph Massaro, Boston University
|
|
2:30 PM
|
Power Analyses of Oncology Clinical Trials with Stratified Randomization
Xiao Fang, Merck; Paul DeLucca, Merck; Fang Liu, Merck & Co., Inc.; Xuan Deng, Merck & Co. Inc; Devan V Mehrotra, Merck & Co., Inc.
|
|
2:35 PM
|
Something Out of Nothing? The Influence of 0-0 Studies in Bayesian Meta-Analysis of Drug Safety Studies
Zhaohu(Jonathan) Fan, University of Cincinnati ; Dungang Liu, University of Cincinnati; Yuejie Chen , North Carolina State University; Nanhua Zhang, Cincinnati Children's Hospital Medical Center
|
|
2:40 PM
|
Incorporating Historical Controls in Analyses of Clinical Trial Data: An Empirical Power Prior Approach
Duncan Rotich, Bristol Myers Squibb; Yun Shen, Bristol Myers Squibb; Kay Tatsuoka, Bristol Myers Squibb
|
|
2:45 PM
|
Do unadjusted pilot analyses lead to biased decision in proceeding to a larger trial?
Robert Montgomery, University of Kansas Medical Center
|
|
2:50 PM
|
Optimizing Precision and Power in COVID-19 Trials by Covariate Adjustment
Nicholas Williams, Weill Cornell Medicine; Ivan Diaz, Weill Cornell Medical College; Michael Rosenblum, Johns Hopkins University
|
|
2:55 PM
|
Collaborative Biostatistics as a Bridge from Preclinical Discovery to Population Data Science
Emily Slade, University of Kentucky; Heather Bush, University of Kentucky
|
|
3:00 PM
|
Interim Analysis Incorporating Intermediate Binary Responses
Gang (Gerry) Li, Alexion Pharmaceuticals; Jiuzhou Wang, University of Minnesota Twin Cities; Jingnan (Jenna) Zhang, Alexion Pharmaceuticals
|
|
3:05 PM
|
Predicting Analysis Times in Clinical Trials with Nonproportional Hazards
David Paulucci, Bristol Myers Squibb; Nikolas Weissmueller, Bristol Myers Squibb; Ming Zhou, Bristol Myers Squibb; Kay Tatsuoka, Bristol Myers Squibb
|
|
3:10 PM
|
Realistic Patient-Level Simulators Considering Two Dependent Time-to-Event Endpoints
Yalin Zhu, Merck & Co Inc; Jing Zhao, Merck & Co., Inc.; Jing Wei, University of Kentucky
|
|
3:15 PM
|
Floor Discussion
|
